PumaRx Registry Trial for Solid Tumors
This study is an observational registry looking at the RenovoCath® device, which helps deliver chemotherapy directly to solid tumors. It's designed to track how safe and effective RenovoCath® is in a real-world setting. Researchers will be looking at any side effects from the chemotherapy delivered by RenovoCath®, as well as any issues related to the delivery procedure itself. You might be able to join if you are at least 18 years old, have been diagnosed with a solid tumor, and are willing to share your medical records. The study aims to enroll up to 1000 people. The current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will collect information about your care without influencing your treatment decisions. Up to 1000 participants will be enrolled.
- What's involved
- You would provide informed consent and allow researchers to access your medical records, including past treatment history. You or your family may be contacted periodically to check on your survival.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for survival outcomes. Safety and performance will be assessed from the first treatment until 30 days after the last treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PumaRx Registry Trial
At a glance
Conditions
NCT06805461
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Baptist Health South Florida
Coral Gables, Floridano site contact published
Recruiting
The University of Vermont Medical Center
Burlington, Vermontno site contact published
Recruiting
University of Pennsylvania Medical Center
Pittsburgh, Pennsylvaniano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety of RenovoCath® as assessed by the number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.From the time of the first treatment, until 30 days after the last treatment
Number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.
- Performance of RenovoCath® as assessed by the number of participants experiencing adverse events related to the inter-arterial drug delivery procedure.From the time of the first treatment, until 30 days after the last treatment
Track the performance of RenovoCath® in a real-world setting delivering a variety of therapeutic agents